Type 2 Diabetes | Disease Landscape & Forecast | G7 | 2022

The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging therapies expected to launch will offer superior dosing and efficacy over current therapies. Notable market growth is also expected to come from the sodium-glucose cotransporter-2 (SGLT-2) inhibitors and the glucagon-like peptide-1 (GLP-1) receptor agonists, owing to their efficacy in glycemic control and weight loss and demonstration of cardiovascular (CV) benefits. However, increasing genericization will build market access pressures on the use of branded therapies, most notably after the arrival of generic DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists.


  • What are the drivers and constraints in the T2D market, and how will the market evolve over the forecast period?
  • How has the launch of Novo Nordisk’s Rybelsus affected the prescribing of injectable GLP-1 receptor agonists such as Eli Lilly’s Trulicity and Novo Nordisk’s Ozempic in the United States? How will the therapy be positioned in the European market?
  • Will label expansions of the SGLT-2 inhibitors—AstraZeneca’s Farxiga and Johnson & Johnson’s Invokana—affect the uptake of Boehringer Ingelheim / Eli Lilly’s Jardiance?
  • What do key opinion leaders think about emerging therapies such as Eli Lilly’s tirzepatide, Novo Nordisk’s insulin icodec, Oramed Pharmaceuticals’ ORMD-0801, and Poxel’s imeglimin?


Geographies: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: prevalence of T2D by country with population-specific diagnosed and drug-treatment rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2030, segmented by brands / generics.

Emerging therapies: Phase III/PR: 5 drugs; coverage of select preclinical, Phase I, and Phase II products.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report